The Latest Breaking News from Gilead

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

Gilead Sciences is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.

These three dividend-paying growth stocks are worth a look at current levels as the odds rise for Fed rate cuts.

More than 300 politicians, health experts and celebrities on Thursday called for US pharmaceutical giant Gilead to allow cheap, generic versions of a promising new HIV drug to be produced so it can reach people in developing countries most affected by the deadly disease.

Gilead Sciences has underperformed the broader market YTD, but Wall Street analysts are still cautiously optimistic about the stock’s prospects.

Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.

June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed on sentiment, while market participants braced for a new round of U.S. economic data and quarterly reports…

Lawsuit against Gilead Sciences raises concerns about innovation impact in drug development and potential implications on future product development.